85%Confidence
0Views
FDASource
2026-04-08Date
Summary
Teva faces a Class II recall for Octreotide Acetate due to sterility concerns at its Greek contract manufacturer, indicating potential supply chain quality control failures. This could impact Teva's revenue from this product and damage its reputation for reliable manufacturing.
Actionable: Monitor Teva's stock for potential volatility and assess the financial impact of the recall and any related regulatory actions.
AI Confidence: 85%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now